/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Immunity is an early-stage landscape with 8 programs across 6 companies. 1 program is in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
67%
Small molecule
4 of 6 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 88% of 8 pipeline programs.
Analysis
39
clinical trials
Clinical Trials
39 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)